BioWorld - Tuesday, April 28, 2026

BioWorld Science

Jan. 3, 2007

View Archived Issues

SKI-606 active in chronic myelogenous leukemia in phase I study

Read More

RHAMM/CD168-R3 peptide vaccine tested in AML, MDS and MM patients

Read More

Snapshots on MAb-based therapies for hematologic malignancies

Read More

Sanofi-aventis enters new option agreement for ImmunoGen's TAP technology

Read More

Bioequivalence study of ANX-530 cleared to begin

Read More

Targeting S1P3 may be useful to treat atherosclerosis

Read More

MedImmune to develop anti-ICOS monoclonal antibodies

Read More

LibiGel studied for female sexual dysfunction in phase III trial

Read More

Stiefel completes acquisition of Connetics

Read More

Partial responses in pancreatic cancer study of glufosfamide plus gemcitabine

Read More

Tumor responses in phase II study of CA4P, paclitaxel and carboplatin

Read More

Lorus Therapeutics reviews Q2 developments

Read More

Authorized generic Oxandrin launched by Watson

Read More

Oscient amends Factive license agreement with LG Life Sciences

Read More

Altana completes sale of pharma business to Nycomed

Read More

3M completes sale of pharma business in Americas

Read More

WelChol filed for treatment of type 2 diabetes

Read More

Novel antidiabetic agents claimed in recent patents

Read More

Enrollment open in phase II study of PX-12 for advanced pancreatic cancer

Read More

Stimuvax NSCLC phase III study opens for enrollment

Read More

Recent patents reveal development of novel agents for cardiovascular disorders

Read More

Novel agents for asthma, COPD, etc. described

Read More